KR20230162662A - 핵산 메틸화 분석을 통해 암을 검출하는 방법 및 시스템 - Google Patents
핵산 메틸화 분석을 통해 암을 검출하는 방법 및 시스템 Download PDFInfo
- Publication number
- KR20230162662A KR20230162662A KR1020237036681A KR20237036681A KR20230162662A KR 20230162662 A KR20230162662 A KR 20230162662A KR 1020237036681 A KR1020237036681 A KR 1020237036681A KR 20237036681 A KR20237036681 A KR 20237036681A KR 20230162662 A KR20230162662 A KR 20230162662A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- genomic regions
- methylation
- panel
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 521
- 201000011510 cancer Diseases 0.000 title claims abstract description 439
- 238000000034 method Methods 0.000 title claims abstract description 272
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 260
- 230000011987 methylation Effects 0.000 title claims abstract description 259
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 175
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 142
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 142
- 238000004458 analytical method Methods 0.000 title claims description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 213
- 208000035475 disorder Diseases 0.000 claims abstract description 168
- 230000002062 proliferating effect Effects 0.000 claims abstract description 135
- 238000012163 sequencing technique Methods 0.000 claims abstract description 86
- 238000010801 machine learning Methods 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 61
- 238000012549 training Methods 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 45
- 238000012164 methylation sequencing Methods 0.000 claims abstract description 22
- 230000004044 response Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 176
- 239000000523 sample Substances 0.000 claims description 132
- 108020004414 DNA Proteins 0.000 claims description 124
- 239000012472 biological sample Substances 0.000 claims description 123
- 102000053602 DNA Human genes 0.000 claims description 122
- 210000001519 tissue Anatomy 0.000 claims description 79
- 206010009944 Colon cancer Diseases 0.000 claims description 67
- 208000029742 colonic neoplasm Diseases 0.000 claims description 65
- 230000035945 sensitivity Effects 0.000 claims description 64
- 206010060862 Prostate cancer Diseases 0.000 claims description 51
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 51
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 50
- 210000001072 colon Anatomy 0.000 claims description 44
- 238000003752 polymerase chain reaction Methods 0.000 claims description 44
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 43
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 43
- 201000002528 pancreatic cancer Diseases 0.000 claims description 43
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 43
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 42
- 201000005202 lung cancer Diseases 0.000 claims description 42
- 208000020816 lung neoplasm Diseases 0.000 claims description 42
- 108091029430 CpG site Proteins 0.000 claims description 41
- 206010033128 Ovarian cancer Diseases 0.000 claims description 41
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 41
- 206010006187 Breast cancer Diseases 0.000 claims description 40
- 208000026310 Breast neoplasm Diseases 0.000 claims description 40
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 40
- 201000007270 liver cancer Diseases 0.000 claims description 40
- 208000014018 liver neoplasm Diseases 0.000 claims description 40
- 238000004422 calculation algorithm Methods 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 37
- 239000008280 blood Substances 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 230000003321 amplification Effects 0.000 claims description 35
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 35
- 210000002307 prostate Anatomy 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 33
- 230000015654 memory Effects 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 31
- 238000003745 diagnosis Methods 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 108091029523 CpG island Proteins 0.000 claims description 28
- 206010020718 hyperplasia Diseases 0.000 claims description 27
- 230000001672 cytoproliferative effect Effects 0.000 claims description 26
- 210000004072 lung Anatomy 0.000 claims description 26
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 21
- 238000012544 monitoring process Methods 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 21
- 210000000481 breast Anatomy 0.000 claims description 20
- 229940035893 uracil Drugs 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 19
- 210000002381 plasma Anatomy 0.000 claims description 19
- 238000012706 support-vector machine Methods 0.000 claims description 16
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 14
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 14
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 14
- 201000004101 esophageal cancer Diseases 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 201000002510 thyroid cancer Diseases 0.000 claims description 14
- 206010005003 Bladder cancer Diseases 0.000 claims description 13
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 13
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 13
- 206010017758 gastric cancer Diseases 0.000 claims description 13
- 201000011549 stomach cancer Diseases 0.000 claims description 13
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 12
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 12
- 210000001124 body fluid Anatomy 0.000 claims description 12
- 239000010839 body fluid Substances 0.000 claims description 12
- 230000002611 ovarian Effects 0.000 claims description 12
- 210000002700 urine Anatomy 0.000 claims description 12
- 210000000601 blood cell Anatomy 0.000 claims description 11
- 230000000112 colonic effect Effects 0.000 claims description 11
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 10
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims description 10
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 10
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 10
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims description 10
- 206010046766 uterine cancer Diseases 0.000 claims description 10
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 8
- 238000013528 artificial neural network Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 238000013145 classification model Methods 0.000 claims description 8
- 239000002853 nucleic acid probe Substances 0.000 claims description 8
- 238000007637 random forest analysis Methods 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 6
- 210000003608 fece Anatomy 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 6
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 6
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 6
- 210000001685 thyroid gland Anatomy 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 238000013135 deep learning Methods 0.000 claims description 4
- 238000006911 enzymatic reaction Methods 0.000 claims description 4
- 238000000513 principal component analysis Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 238000013179 statistical model Methods 0.000 claims description 4
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 210000005267 prostate cell Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 230000008719 thickening Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 57
- 238000012216 screening Methods 0.000 abstract description 14
- 206010061818 Disease progression Diseases 0.000 abstract description 5
- 230000005750 disease progression Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 61
- 229920002477 rna polymer Polymers 0.000 description 47
- 238000003556 assay Methods 0.000 description 46
- 238000005259 measurement Methods 0.000 description 36
- 230000000875 corresponding effect Effects 0.000 description 32
- 238000012545 processing Methods 0.000 description 32
- 238000003860 storage Methods 0.000 description 31
- 230000008569 process Effects 0.000 description 19
- 238000002591 computed tomography Methods 0.000 description 18
- 229940104302 cytosine Drugs 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 16
- 238000007481 next generation sequencing Methods 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000011144 upstream manufacturing Methods 0.000 description 13
- 238000001369 bisulfite sequencing Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 230000007067 DNA methylation Effects 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 229940113082 thymine Drugs 0.000 description 7
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 6
- 238000009534 blood test Methods 0.000 description 6
- 238000011976 chest X-ray Methods 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 238000012175 pyrosequencing Methods 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000007847 digital PCR Methods 0.000 description 5
- 238000011304 droplet digital PCR Methods 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000003559 RNA-seq method Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 238000007473 univariate analysis Methods 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 108091092259 cell-free RNA Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002052 colonoscopy Methods 0.000 description 3
- 230000009615 deamination Effects 0.000 description 3
- 238000006481 deamination reaction Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001621 AMOLED Polymers 0.000 description 2
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 description 2
- 230000030933 DNA methylation on cytosine Effects 0.000 description 2
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013527 convolutional neural network Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000013079 data visualisation Methods 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007672 fourth generation sequencing Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000007855 methylation-specific PCR Methods 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007841 sequencing by ligation Methods 0.000 description 2
- 239000010454 slate Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- SBHSUMUTJOPRIK-HPFNVAMJSA-N 5-(beta-D-glucosylmethyl)cytosine Chemical compound NC1=NC(=O)NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SBHSUMUTJOPRIK-HPFNVAMJSA-N 0.000 description 1
- BLQMCTXZEMGOJM-UHFFFAOYSA-N 5-carboxycytosine Chemical compound NC=1NC(=O)N=CC=1C(O)=O BLQMCTXZEMGOJM-UHFFFAOYSA-N 0.000 description 1
- FHSISDGOVSHJRW-UHFFFAOYSA-N 5-formylcytosine Chemical compound NC1=NC(=O)NC=C1C=O FHSISDGOVSHJRW-UHFFFAOYSA-N 0.000 description 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- -1 DNA Chemical class 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 206010072082 Environmental exposure Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102100026456 POU domain, class 3, transcription factor 3 Human genes 0.000 description 1
- 101710133393 POU domain, class 3, transcription factor 3 Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 206010065918 Prehypertension Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006326 desulfonation Effects 0.000 description 1
- 238000005869 desulfonation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000007812 electrochemical assay Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012628 principal component regression Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013106 supervised machine learning method Methods 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000000700 time series analysis Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002235 transmission spectroscopy Methods 0.000 description 1
- 238000013107 unsupervised machine learning method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Evolutionary Biology (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Software Systems (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166641P | 2021-03-26 | 2021-03-26 | |
| US63/166,641 | 2021-03-26 | ||
| PCT/US2022/021662 WO2022204358A1 (en) | 2021-03-26 | 2022-03-24 | Methods and systems for detecting cancer via nucleic acid methylation analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230162662A true KR20230162662A (ko) | 2023-11-28 |
Family
ID=83396062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237036681A Pending KR20230162662A (ko) | 2021-03-26 | 2022-03-24 | 핵산 메틸화 분석을 통해 암을 검출하는 방법 및 시스템 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230178181A1 (https=) |
| EP (1) | EP4314322A4 (https=) |
| JP (1) | JP2024512627A (https=) |
| KR (1) | KR20230162662A (https=) |
| CN (1) | CN117413072A (https=) |
| AU (1) | AU2022245306A1 (https=) |
| CA (1) | CA3213101A1 (https=) |
| WO (1) | WO2022204358A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060716A1 (en) | 2017-09-25 | 2019-03-28 | Freenome Holdings, Inc. | SAMPLE EXTRACTION METHODS AND SYSTEMS |
| AU2020283042B2 (en) | 2019-05-31 | 2026-02-19 | Freenome Holdings, Inc. | Methods and systems for high-depth sequencing of methylated nucleic acid |
| CA3178302A1 (en) | 2020-03-31 | 2021-10-07 | Freenome Holdings, Inc. | Methods and systems for detecting colorectal cancer via nucleic acid methylation analysis |
| WO2021228418A1 (en) | 2020-05-15 | 2021-11-18 | Universal Diagnostics, S.L. | Methods and systems for identifying methylation biomarkers |
| WO2022076237A1 (en) | 2020-10-05 | 2022-04-14 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| AU2021409465A1 (en) | 2020-12-21 | 2023-08-03 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| WO2024096536A1 (ko) * | 2022-10-31 | 2024-05-10 | 주식회사 지씨지놈 | 폐암 진단용 dna 메틸화 마커 및 이의 용도 |
| JP2025539719A (ja) * | 2022-10-31 | 2025-12-09 | ジーシー ゲノム コーポレーション | 肝癌診断用ｄｎａメチル化マーカー及びその用途 |
| JP2025539741A (ja) * | 2022-11-16 | 2025-12-09 | グレイル インコーポレイテッド | モデルベースの特徴化及び分類の最適化 |
| US12606872B2 (en) | 2022-11-16 | 2026-04-21 | Universal Diagnostics, S.A. | Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers |
| WO2025128926A1 (en) * | 2023-12-13 | 2025-06-19 | Amazon Technologies, Inc. | Methods of identifying and treating individuals with elevated cancer risk |
| US20250223652A1 (en) * | 2024-01-05 | 2025-07-10 | Harbinger Health, Inc. | Tiered testing for high risk populations |
| CN117904313B (zh) * | 2024-01-18 | 2024-12-24 | 四川大学 | 一种基于酶转化法从精液或精斑中推断年龄的方法及复合体系和引物组合 |
| CN117935909B (zh) * | 2024-01-26 | 2024-10-01 | 哈尔滨工业大学 | 基于电信号与序列融合的第三代测序dna甲基化检测方法 |
| WO2025207830A1 (en) * | 2024-03-27 | 2025-10-02 | Freenome Holdings, Inc. | Methods and systems for inferring gene expression using cell-free dna fragments |
| US20250372202A1 (en) * | 2024-05-28 | 2025-12-04 | Nec Laboratories America, Inc. | Learning interdependent biomarkers of disease progression for medical decision making |
| WO2025251032A1 (en) * | 2024-05-31 | 2025-12-04 | Helio Health Inc. | Liver cancer methylation markers and machine models |
| CN118588172B (zh) * | 2024-06-07 | 2025-01-17 | 首都医科大学附属北京积水潭医院 | 用于监测多发性骨髓瘤微小残留病的计算机装置 |
| CN118888009B (zh) * | 2024-09-27 | 2024-12-20 | 安徽安龙基因科技有限公司 | 一种肝癌检测系统、试剂盒及其应用 |
| CN120148626A (zh) * | 2025-02-21 | 2025-06-13 | 上海小荷医学检验实验室有限公司 | 用于肿瘤检测的方法、装置、设备和程序产品 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018057888A1 (en) * | 2016-09-23 | 2018-03-29 | Driver, Inc. | Integrated systems and methods for automated processing and analysis of biological samples, clinical information processing and clinical trial matching |
| CN119753091A (zh) * | 2018-04-02 | 2025-04-04 | 格里尔公司 | 用于扩增与癌症相关联的cfDNA分子的化验板 |
| CN112888459B (zh) * | 2018-06-01 | 2023-05-23 | 格里尔公司 | 卷积神经网络系统及数据分类方法 |
-
2022
- 2022-03-24 WO PCT/US2022/021662 patent/WO2022204358A1/en not_active Ceased
- 2022-03-24 CN CN202280038299.2A patent/CN117413072A/zh active Pending
- 2022-03-24 JP JP2023559736A patent/JP2024512627A/ja active Pending
- 2022-03-24 CA CA3213101A patent/CA3213101A1/en active Pending
- 2022-03-24 KR KR1020237036681A patent/KR20230162662A/ko active Pending
- 2022-03-24 AU AU2022245306A patent/AU2022245306A1/en active Pending
- 2022-03-24 EP EP22776625.0A patent/EP4314322A4/en active Pending
-
2023
- 2023-02-01 US US18/163,174 patent/US20230178181A1/en active Pending
- 2023-09-22 US US18/472,529 patent/US20240084397A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4314322A1 (en) | 2024-02-07 |
| CN117413072A (zh) | 2024-01-16 |
| US20230178181A1 (en) | 2023-06-08 |
| US20240084397A1 (en) | 2024-03-14 |
| AU2022245306A1 (en) | 2023-10-12 |
| JP2024512627A (ja) | 2024-03-19 |
| WO2022204358A1 (en) | 2022-09-29 |
| EP4314322A4 (en) | 2025-05-21 |
| CA3213101A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240084397A1 (en) | Methods and systems for detecting cancer via nucleic acid methylation analysis | |
| US12410480B2 (en) | Methods and systems for detecting colorectal cancer via nucleic acid methylation analysis | |
| US12454724B2 (en) | Methods and systems for high-depth sequencing of methylated nucleic acid | |
| US20230160019A1 (en) | Rna markers and methods for identifying colon cell proliferative disorders | |
| US20250146081A1 (en) | Tcr/bcr profiling for cell-free nucleic acid detection of cancer | |
| EP4652296A1 (en) | Methods and systems for detecting and assessing liver conditions | |
| HK40107669A (zh) | 用於通过核酸甲基化分析检测癌症的方法和系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231025 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250310 Comment text: Request for Examination of Application |